← FDA DRUG APPROVALS

FDA ANDA · ANDA219777

MAGNESIUM SULFATE

magnesium sulfate heptahydrate

Sponsor: ASPIRO

APPLICATION
ANDA219777
TYPE
ANDA
ORIGINAL APPROVAL
2025-05-28
LATEST ACTION
2025-05-28
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INTRAMUSCULAR, INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

MAGNESIUM SULFATEPrescription
MAGNESIUM SULFATE 1GM/2ML (500MG/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATEPrescription
MAGNESIUM SULFATE 25GM/50ML (500MG/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATEPrescription
MAGNESIUM SULFATE 5GM/10ML (500MG/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATEPrescription
MAGNESIUM SULFATE 10GM/20ML (500MG/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS

Approval history

2025-05-28UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →